Hepatitis C virus common transmission routes and HCV coinfection is frequent in persons living with HIV. Liver enzyme elevation following the initiation of antiretroviral therapy is frequently seen in HIV-infected patients with chronic liver disease, particularly those with chronic hepatitis C. This complication may lead to treatment discontinuation, complicating HIV therapeutic management. Multiple factors influence the risk of liver toxicity under antiretroviral therapy, including the specific drug in use (e.g. use of full doses of ritonavir), and environmental factors (e.g. alcohol abuse). However a beneficial effect of antiretroviral therapy on liver disease has been supported by some studies. Despite increasing knowledge of HCV/HIV coinfection, there is no clear consensus on how to treat HIV in HCV-coinfected patients An Italian group of experts were invited to discuss in detail the current risks and implications of antiretroviral treatment in HIV-infected persons with chronic hepatitis C, and their main conclusions are summarized in this consensus document.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop|
|Citazione:||Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop / Carosi, G; Puoti, M; Antonucci, G; DE LUCA, Andrea; Maserati, R; Torti, C; Bonfanti, P; Bonora, S; Bruno, R; Gaeta, G; Antinori, A; Monforte, A; Orani, A; Sagnelli, E; Cargnel, A; Cauda, R; Mazzotta, F; Pastore, G; Suter, F; Vullo, V.. - In: AIDS REVIEWS. - ISSN 1139-6121. - 7:3(2005), pp. 161-167.|
|Appare nelle tipologie:||1.1 Articolo in rivista|